Nadia Karim, MSc

Amgen Ltd., United Kingdom

Poster(s):

• (316) Cost-effectiveness of sotorasib vs. adagrasib in KRAS G12C-mutated previously treated non-small cell lung cancer (NSCLC): An economic evaluation on Phase 3 trial results
  Wednesday, October 29, 2025